Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

被引：14

作者：

Abeykoon, Jithma P. ^{[1
]}

Vaxman, Julia ^{[1
]}

Patel, Sanjay V. ^{[2
]}

Kumar, Shaji ^{[1
]}

Malave, Gabriella C. ^{[1
]}

Young, Kimberly S. ^{[1
]}

Ailawadhi, Sikander ^{[3
]}

Larsen, Jeremy T. ^{[4
]}

Dispenzieri, Angela ^{[1
]}

Muchtar, Eli ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Kourelis, Taxiarchis ^{[1
]}

Leung, Nelson ^{[1
]}

Warsame, Rahma ^{[1
]}

Go, Ronald S. ^{[1
]}

Bergsagel, Leif ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Gertz, Morie A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[2] Mayo Clin, Dept Ophthalmol, Rochester, MN USA

[3] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Div Hematol, Scottsdale, AZ USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 01期

关键词：

antibody-drug conjugate; B-cell maturation antigen; monoclonal gammopathy; ANTIBODY; DRUG;

D O I：

10.1111/bjh.18298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

引用

页码：95 / 99

页数：5

共 50 条

[21] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
Sheikh, Semira
Lebel, Eyal
Trudel, Suzanne
FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
[22] Corneal epithelial toxicity induced by belantamab mafodotin
Patel, Savan V.
Joshi, Nisarg
Thareja, Tarika
Jhanji, Vishal
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 49 (09): : 1113 - 1115
[23] Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Theodorakakou, Foteini
Spiliopoulou, Vassiliki
Kastritis, Efstathios
Terpos, Evangelos
Dimopoulos, Meletios
Gavriatopoulou, Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S203 - S204
[24] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha, Attaya
Bahlis, Nizar
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Oriol, Albert
Voorhees, Peter M.
Alonso, Aranzazu A.
Callander, Natalie S.
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Lamacchia, John
Patel, Nashita
Williams, Danae
Jewell, Roxanne. C.
Zhou, Xiangdong
Gupta, Ira
Opalinska, Joanna
Nooka, Ajay K.
CANCER, 2024, 130 (15) : 2629 - 2641
[25] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
Popat, Rakesh
Kazantzi, Aikaterini
Kleinman, David
Lichenstein, Carolyn
Paka, Prani
Salter, John
Byrne, Julie
Doherty, Allison
Degli Esposti, Simona
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
[26] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
Melody, Megan
Przybylski, Daniel
Robinson, Adam
Lin, Adam
Gordon, Leo
Adekola, Kehinde
Singhal, Seema
Mehta, Jayesh
Moreira, Jonathan
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
[27] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Baines, Andrea C.
Ershler, Rachel
Kanapuru, Bindu
Xu, Qing
Shen, Guoxiang
Li, Liang
Ma, Lian
Okusanya, Olanrewaju O.
Simpson, Natalie E.
Nguyen, Wanda
Theoret, Marc R.
Pazdur, Richard
Gormley, Nicole J.
CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
[28] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
Condorelli, Annalisa
Garibaldi, Bruno
Gagliano, Caterina
Romano, Alessandra
Del Fabro, Vittorio
Parrinello, Nunziatina Laura
Longo, Antonio
Cosentino, Sebastiano
Di Raimondo, Francesco
Conticello, Concetta
ACTA HAEMATOLOGICA, 2024, 147 (04) : 493 - 498
[29] Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin
Menardais, B.
Soethoudt, M.
Espargilliere, D.
Mouriaux, F.
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (05): : 766 - 768
[30] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
Stocker, Nicolas
HEMATOLOGIE, 2020, 26 (02): : 99 - 100

← 1 2 3 4 5 →